Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Presynaptic neuron monoamine release is the process by which monoaminergic neurons release monoamine neurotransmitters—primarily dopamine, norepinephrine (noradrenaline), and serotonin (5-HT)—from their presynaptic terminals into the synaptic cleft. This release is a key step in chemical synaptic transmission, enabling communication between neurons and modulation of various physiological processes. The process involves synthesis and storage of monoamines in vesicles, calcium-triggered exocytosis, receptor binding, reuptake via transporters (DAT, NET, SERT), and enzymatic degradation. Certain drugs, like monoamine releasing agents (MRAs), can induce non-vesicular release, leading to increased extracellular concentrations of monoamines. This process plays a critical role in regulating mood, arousal, attention, motor control, and autonomic functions, and its dysfunction is implicated in psychiatric disorders.
Ca2+-dependent exocytosis, drug-induced reverse transport via DAT/NET/SERT
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Presynaptic Neuron Monoamine Release.